Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinosarcoma 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 6Biopsy 6pembrolizumab 3X-Rays 3Nivolumab 3olaparib 2durvalumab 2ceralasertib 2Paclitaxel 2Immunoglobulin G 2Carboplatin 2trastuzumab deruxtecan 1sargramostim 1ribociclib 1pelcitoclax 1cobimetinib 1cediranib 1capivasertib 1cabozantinib 1atezolizumab 1Tissue Banks 1Taxes 1TIC10 compound 1Radiation 1Phantoms, Imaging 1Minimally Invasive Surgical Procedures 1Ipilimumab 1Indocyanine Green 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × pelcitoclax × 1 year × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡